Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xenetic Biosciences Inc (NQ: XBIO )

4.147 UNCHANGED
Streaming Delayed Price Updated: 1:08 PM EDT, Aug 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 4.147
Bid (Size) 1.720 (1)
Ask (Size) 6.780 (2)
Prev. Close 4.147
Today's Range 4.147 - 4.147
52wk Range 2.780 - 5.970
Shares Outstanding 1,542,139
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
Via ACCESSWIRE
XBIO Stock Earnings: Xenetic Biosciences Meets EPS, Beats Revenue for Q2 2024
XBIO stock results show that Xenetic Biosciences met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
+16.33%
+16.33%
1 Month
-8.41%
-8.41%
3 Month
+8.57%
+8.57%
6 Month
+6.07%
+6.07%
1 Year
+6.07%
+6.07%

More News

Read More
Xenetic Biosciences, Inc. Announces Executive Leadership Transition
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
Via ACCESSWIRE
XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
XBIO Stock Earnings: Xenetic Biosciences Beats EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Xenetic Biosciences: Q3 Earnings Insights
Via Benzinga
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results
Via ACCESSWIRE
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series
Via ACCESSWIRE
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
Via ACCESSWIRE
Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
Via ACCESSWIRE
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Via ACCESSWIRE
Lack Of Catalysts Prompts Analyst To Downgrade Xenetic Biosciences
Via Benzinga
Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update
Via ACCESSWIRE
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison
Via ACCESSWIRE
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
Via ACCESSWIRE
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development
Via ACCESSWIRE
Mifepristone Abortion Pill Access in Limbo: Justice Department May Ask Supreme Court's Intervention
Via Benzinga
Women's Reproductive Rights: US Court Preserves Access To Abortion Pill For Now, But With Tighter Rules
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.